Aerie Pharmaceuticals (AERI) Sets New 12-Month Low at $38.16

Aerie Pharmaceuticals Inc (NASDAQ:AERI) hit a new 52-week low on Friday . The company traded as low as $38.16 and last traded at $38.53, with a volume of 7809 shares traded. The stock had previously closed at $39.01.

A number of equities research analysts have recently weighed in on the company. Oppenheimer assumed coverage on Aerie Pharmaceuticals in a research report on Monday, December 3rd. They issued a “buy” rating and a $64.00 price objective on the stock. BidaskClub lowered Aerie Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Tuesday, October 9th. ValuEngine lowered Aerie Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, November 27th. Mizuho reiterated a “buy” rating and issued a $77.00 price objective on shares of Aerie Pharmaceuticals in a research report on Tuesday, November 27th. Finally, Zacks Investment Research upgraded Aerie Pharmaceuticals from a “sell” rating to a “buy” rating and set a $60.00 price objective on the stock in a research report on Wednesday, October 10th. Two analysts have rated the stock with a sell rating, one has assigned a hold rating and eleven have issued a buy rating to the stock. The stock presently has an average rating of “Buy” and an average price target of $79.25.

The company has a market cap of $1.74 billion, a P/E ratio of -11.34 and a beta of 0.92.

Aerie Pharmaceuticals (NASDAQ:AERI) last released its earnings results on Tuesday, November 6th. The company reported ($1.73) EPS for the quarter, missing the Zacks’ consensus estimate of ($1.33) by ($0.40). The firm had revenue of $7.30 million during the quarter, compared to the consensus estimate of $5.63 million. As a group, research analysts anticipate that Aerie Pharmaceuticals Inc will post -5.48 earnings per share for the current year.

In other news, Director Gerald D. Cagle bought 2,000 shares of the stock in a transaction dated Friday, November 16th. The stock was bought at an average price of $41.75 per share, for a total transaction of $83,500.00. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Casey C. Kopczynski sold 11,000 shares of the firm’s stock in a transaction that occurred on Monday, October 1st. The shares were sold at an average price of $60.56, for a total value of $666,160.00. Following the completion of the transaction, the insider now owns 138,187 shares of the company’s stock, valued at approximately $8,368,604.72. The disclosure for this sale can be found here. In the last 90 days, insiders sold 99,605 shares of company stock valued at $5,708,259. 10.53% of the stock is currently owned by company insiders.

Large investors have recently made changes to their positions in the business. Girard Partners LTD. purchased a new position in Aerie Pharmaceuticals during the third quarter valued at $105,000. Fox Run Management L.L.C. purchased a new position in Aerie Pharmaceuticals during the third quarter valued at $201,000. First Republic Investment Management Inc. purchased a new position in Aerie Pharmaceuticals during the second quarter valued at $276,000. Public Employees Retirement Association of Colorado raised its stake in Aerie Pharmaceuticals by 48.6% during the third quarter. Public Employees Retirement Association of Colorado now owns 4,370 shares of the company’s stock valued at $269,000 after buying an additional 1,430 shares during the last quarter. Finally, GW Henssler & Associates Ltd. purchased a new position in Aerie Pharmaceuticals during the third quarter valued at $334,000.

COPYRIGHT VIOLATION WARNING: This piece was published by Community Financial News and is owned by of Community Financial News. If you are viewing this piece on another website, it was illegally copied and reposted in violation of United States and international copyright & trademark laws. The original version of this piece can be accessed at https://www.com-unik.info/2018/12/16/aerie-pharmaceuticals-aeri-sets-new-12-month-low-at-38-16.html.

Aerie Pharmaceuticals Company Profile (NASDAQ:AERI)

Aerie Pharmaceuticals, Inc, an ophthalmic pharmaceutical company, focuses on the discovery, development, and commercialization of first-in-class therapies for the treatment of glaucoma and other eye diseases. Its lead product is Rhopressa, a once-daily eye drop to reduce elevated intraocular pressure (IOP) in patients with glaucoma or ocular hypertension.

Read More: What is a Market Correction?

Receive News & Ratings for Aerie Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aerie Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit